Showing 241 - 260 results of 1,176 for search '"time series"', query time: 0.07s Refine Results
  1. 241

    Effect of Implementing a Free Delivery Service Policy on Women’s Utilization of Facility-Based Delivery in Central Ethiopia: An Interrupted Time Series Analysis by Ayalneh Demissie, Alemayehu Worku, Yemane Berhane

    Published 2020-01-01
    “…Routine monthly data were extracted from the District Health Information System and verified using data from the delivery ward logbooks across the study facilities. An interrupted time-series analysis was conducted to assess the effect of the intervention. …”
    Get full text
    Article
  2. 242
  3. 243

    Scaling and intermittent properties of oceanic and atmospheric <i>p</i>CO<sub>2</sub> time series and their difference in a turbulence framework by K. Robache, F. G. Schmitt, Y. Huang, Y. Huang

    Published 2025-01-01
    “…The difference between these time series, the sea surface temperature data and the sea surface salinity data were also studied. …”
    Get full text
    Article
  4. 244

    Improving Air Quality and Childhood Respiratory Health in Mongolia: The Impact of the Raw Coal Ban and COVID-19 Restrictions—An Interrupted Time-Series Analysis by Emma Dickinson-Craig, Terkhen Turbat, Karla Hemming, Francis D. Pope, Suzanne E. Bartington, Suvdaa Anjaa, Sumiya Davaa, Rosie Day, Damdindorj Boldbaatar, Chimedsuren Ochir, David Warburton, Graham Neil Thomas, Jargalsaikhan Badarch, Semira Manaseki-Holland

    Published 2025-01-01
    “…Methods: An interrupted time-series analysis was conducted on air quality (PM<sub>2.5</sub>, PM<sub>10</sub>, SO<sub>2</sub>, CO) and child (<5 y) severe acute respiratory disease, adjusting for coinciding co-events (COVID-19) where necessary. …”
    Get full text
    Article
  5. 245

    Effects of removing reimbursement restrictions on targeted therapy accessibility for non-small cell lung cancer treatment in Taiwan: an interrupted time series study by Jason C Hsu, Chen-Fang Wei, Szu-Chun Yang

    Published 2019-03-01
    “…Another targeted therapy, erlotinib, was initially approved as a third-line therapy in 2007, and it became a second-line therapy in 2008.Objectives This study is aimed towards an exploration of the impacts of the Taiwan NHI reimbursement policies (removing reimbursement restrictions) related to accessibility of targeted therapies.Setting We retrieved 2004–2013 claims data for all patients with lung cancer diagnoses from the NHI Research Database.Design and outcome measures Using an interrupted time series design and segmented regression, we estimated changes in the monthly prescribing rate by patient number and market shares by cost following each modification of the reimbursement policy for gefitinib and erlotinib for NSCLC treatment.Results Totally 92 220 patients with NSCLC were identified. …”
    Get full text
    Article
  6. 246
  7. 247
  8. 248
  9. 249
  10. 250
  11. 251
  12. 252
  13. 253
  14. 254
  15. 255
  16. 256
  17. 257
  18. 258
  19. 259
  20. 260